Click Here For COVID-19 (Coronavirus) Studies

Trials Offered by a Specific Doctor

Kevin Kalinsky, MD, MS

Kevin Kalinsky, M.D., M.S. is an Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency and Hemathology/Oncology fellowship at Tufts Medical Center. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Since joining as a faculty member, Dr. Kalinsky completed a Master's program in Biostatistics, Patient-Oriented Research.

Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. Dr. Kalinsky's research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. The goal of his research is to translate findings developed at the bench to clinical trials for study at the bedside. His work is funded by a number of sources, including the National Institute of Health and SWOG/Hope Foundation.

Clinical Studies Managed By Dr. Kalinsky:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for postmenopausal women with advanced or metastatic breast cancer using study drug MLN0128Millennium Pharmaceuticals, Inc.AAAN6701
Details[CLOSED] Study for women with metastatic triple-negative breast cancer using study drug cobimetinibHoffmann-La RocheAAAO6451
Details[CLOSED] A study for patients with Epithelial Cancer using study drug IMMU-132Immunomedics, IncAAAP0469
Details[CLOSED] A study for patients with metastatic breast cancer using study drug Ricolinostat in combination with nab-paclitaxelAcetylonAAAQ3709
Details[CLOSED] A study for women with breast cancer using a microfluidic device to detect leptomenigeal metastasis (LM)BioceptAAAQ4761
DetailsA study for patients with locally advanced or metastatic breast cancer using study drug GDC-0077Genentech, Inc.AAAR0323
DetailsA study for patients with LIV-1-positive metastatic breast cancer using study drug SGN-LIV1ASeattle Genetics, IncAAAQ9893
Details[CLOSED] Study of Sacituzumab Govitecan in patients with triple-negative breast cancerImmunomedics, Inc.AAAR5627
DetailsOptical Tomographic Imaging in Pre-Surgical Women with Breast CancerInvestigator initiated studyAAAI9154
Details[CLOSED] Study of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast CancerIncyte CorporationAAAM1906
Details[CLOSED] Pre-Surgical Trial of Sombination of Combination of Metformin and Atovastatin in Newly Diagnosed Operable Breast CancerBreast Cancer Research Foundation GrantAAAM2306
Details[CLOSED] Study of using patient's residual tumor to develop a cancer modelChampions Oncology, SWOGAAAN9005
Details[CLOSED] Study of Safety and Efficacy of Eribulin in Combination with Pembrolizumab in Breast Cancer PatientsEisai Inc.AAAP8952
DetailsStudy of efficacy of ribociclib plus fulvestrant in patients with metastatic breast cancerNovartisAAAP9506
Details[CLOSED] Study of Escalating Doses of Study Drug in Patients with HER2 Positive Breast CancerGenentech, Inc.AAAR6895
DetailsStudy to Predict Your Therapeutic Response (I-SPY 2 Trial)QuantumLeap Healthcare Collaborative QLHCAAAR1925
DetailsStudy of Drug Combination in Subjects with Triple Negative Breast Cancer or Colorectal Cancer with Liver MetastasesAmgenAAAR2673
Details[CLOSED] Study of Combination Drug in Patients with Advanced Triple Negative Breast Cancer (TNBC)Calithera Biosciences Inc.AAAR2902
Details[CLOSED] Study of Drug in Adults with Metastatic or Locally Advanced Unresectable Solid TumorsCytomX Therapeutics, Inc.AAAR5081
DetailsStudy of Select Immunotherapy Combinations in Patients with Triple Negative Breast CancerNovartisAAAS1826
DetailsA Study of ZN-c5 in Subjects With Breast CancerZeno Alpha Inc.AAAS0192
Details[CLOSED] Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsCalithera Biosciences, IncAAAS2587
DetailsStudy of IMMU-132 in HR+/HER2- Metastatic Breast Cancer (TROPICS-02)Immunomedics, Inc.AAAS3688
DetailsEvaluation of Biomarkers in Subjects with Estrogen Receptor-Positive, HER2-Negative Breast CancerZeno Alpha, Inc.AAAS6670
DetailsStudy of PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast CancerPhoenix Molecular DesignsAAAS8152
DetailsStudy for Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerF. HoffmannLa Roche LtdAAAS7062
DetailsA Study of MORAb-202 in Participants With Selected Tumor TypesEisai Inc.AAAS8404